|
1
|
Stewart BW and Wild CP: World Cancer
Report 2014World Health Organization. IARC; Lyon: 2015, View Article : Google Scholar
|
|
2
|
He J and Song X: Advances in association
of estrogen and human non-small cell lung cancer. Zhongguo Fei Ai
Za Zhi. 18:315–320. 2015.PubMed/NCBI
|
|
3
|
Schvartsman G, Ferrarotto R and Massarelli
E: Checkpoint inhibitors in lung cancer: Latest developments and
clinical potential. Ther Adv Med Oncol. 8:460–473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saavedra D and Crombet T: CIMAvax-EGF: A
new therapeutic vaccine for advanced non-small cell lung cancer
patients. Front Immunol. 8:2692017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh AK, Arya RK, Trivedi AK, Sanyal S,
Baral R, Dormond O, Briscoe DM and Datta D: Chemokine receptor
trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
Cytokine Growth Factor Rev. 24:41–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kodama J, Hasengaowa, Kusumoto T, Seki N,
Matsuo T, Ojima Y, Nakamura K, Hongo A and Hiramatsu Y: Association
of CXCR4 and CCR7 chemokine receptor expression and lymph node
metastasis in human cervical cancer. Ann Oncol. 18:70–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo L, Cui ZM, Zhang J and Huang Y:
Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph
node metastasis in epithelial ovarian carcinoma. Chin J Cancer.
30:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen B, Zheng MQ, Lu JW, Jiang Q, Wang TH
and Huang XE: CXCL12-CXCR4 promotes proliferation and invasion of
pancreatic cancer cells. Asian Pac J Cancer Prev. 14:5403–5408.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qiu MY, Li JW and Zheng MH: The chemokine
receptors CXCR4 and CXCR7 in cancer. Chin Oncol. 20:222–226.
2010.
|
|
10
|
Kim M, Koh YJ, Kim KE, Koh BI, Nam DH,
Alitalo K, Kim I and Koh GY: CXCR4 signaling regulates metastasis
of chemoresistant melanoma cells by a lymphatic metastatic niche.
Cancer Res. 70:10411–10421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maderna E, Salmaggi A, Calatozzolo C,
Limido L and Pollo B: Nestin, PDGFRbeta, CXCL12 and VEGF in glioma
patients: Different profiles of (pro-angiogenic) molecule
expression are related with tumor grade and may provide prognostic
information. Cancer Biol Ther. 6:1018–1024. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Driessen WH, Fujii N, Tamamura H and
Sullivan SM: Development of peptide-targeted lipoplexes to
CXCR4-expressing rat glioma cells and rat proliferating endothelial
cells. Mol Ther. 16:516–524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gulati S, Ytterhus B, Granli US, Gulati M,
Lydersen S and Torp SH: Overexpression of c-erbB2 is a negative
pognostic factor in anaplastic astrocytomas. Diagn Pathol.
5:182010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rexer BN, Ghosh R, Narasanna A, Estrada
MV, Chakrabarty A, Song Y, Engelman JA and Arteaga CL: Human breast
cancer cells harboring a gatekeeper T798M mutation in HER2
overexpress EGFR ligands and are sensitive to dual inhibition of
EGFR and Her2. Clin Cancer Res. 19:5390–5401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al Zobair AA, Al Obeidy BF, Yang L, Yang
C, Hui Y, Yu H, Zheng F, Yang G, Xie C, Zhou F, et al: Concomitant
overexpression of EGFR and CXCR4 is associated with worse prognosis
in a new molecular subtype of non-small cell lung cancer. Oncol
Rep. 29:1524–1532. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo Z, Cai S, Fang R, Chen H, Du J, Tan Y,
Ma W, Hu H, Cai S and Liu Y: The synergistic effects of CXCR4 and
EGFR on promoting EGF-mediated metastasis in ovarian cancer cells.
Colloids Surf B Biointerfaces. 60:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel LR, Camacho DF, Shiozawa Y, Pienta
KJ and Taichman RS: Mechanisms of cancer cell metastasis to the
bone: A multistep process. Future Oncol. 7:1285–1297. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shon SK, Kim A, Kim JY, Kim KI, Yang Y and
Lim JS: Bone morphogenetic protein-4 induced by NDRG2 expression
inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res
Commun. 385:198–203. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Faraji SN, Mojtahedi Z, Ghalamfarsa G and
Takhshid MA: N-myc downstream regulated gene 2 overexpression
reduces matrix metalloproteinase-2 and −9 activities and cell
invasion of A549 lung cancer cell line in vitro. Iran J Basic Med
Sci. 18:773–779. 2015.PubMed/NCBI
|
|
21
|
Zuo J, Ishikawa T, Boutros S, Xiao Z,
Humtsoe JO and Kramer RH: Bcl-2 overexpression induces a partial
epithelial to mesenchymal transition and promotes squamous
carcinoma cell invasion and metastasis. Mol Cancer Res. 8:170–182.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao J, Liu X, Yang F, Liu T, Yan Q and
Yang X: By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM
inhibits breast cancer cell growth and metastasis. Oncotarget.
6:27187–27198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su L, Zhou W, Park S, Wain JC, Lynch TJ,
Liu G and Christiani DC: Matrix metalloproteinase-1 promoter
polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers
Prev. 14:567–570. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai J, Li R, Xu X, Zhang L, Wu S, Yang T,
Fang L, Wu J, Zhu X, Li M, et al: URGCP promotes non-small cell
lung cancer invasiveness by activating the NF-kappaB-MMP-9 pathway.
Oncotarget. 6:36489–36504. 2015.PubMed/NCBI
|
|
25
|
Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng
GQ, Wan XX, He QY, Li JH, Qu JQ, et al: Activation of EGFR promotes
squamous carcinoma SCC10A cell migration and invasion via inducing
EMT-like phenotype change and MMP-9-mediated degradation of
E-cadherin. J Cell Biochem. 112:2508–2517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Travis WD: The 2015 WHO classification of
lung tumors. Pathologe. 35 Suppl 2:S1882014. View Article : Google Scholar
|
|
27
|
Zuo J, Wen M, Lei M, Peng X, Yang X and
Liu Z: MiR-210 links hypoxia with cell proliferation regulation in
human Laryngocarcinoma cancer. J Cell Biochem. 116:1039–1049. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dai X, Mao Z, Huang J, Xie S and Zhang H:
The CXCL12/CXCR4 autocrine loop increases the metastatic potential
of non-small cell lung cancer in vitro. Oncol Lett. 5:277–282.
2013.PubMed/NCBI
|
|
29
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling
X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, et al:
Targeting the leukemia microenvironment by CXCR4 inhibition
overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood. 113:6215–6224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peled A and Tavor S: Role of CXCR4 in the
pathogenesis of acute myeloid leukemia. Theranostics. 3:34–39.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ali Sheikh MA, Gunduz M, Nagatsuka H,
Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M,
Yamanaka N, et al: Expression and mutation analysis of epidermal
growth factor receptor in head and neck squamous cell carcinoma.
Cancer Sci. 99:1589–1594. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fung C and Grandis JR: Emerging drugs to
treat squamous cell carcinomas of the head and neck. Expert Opin
Emerg Drugs. 15:355–373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Murakami T, Kawada K, Iwamoto M, Akagami
M, Hida K, Nakanishi Y, Kanda K, Kawada M, Seno H, Taketo MM, et
al: The role of CXCR3 and CXCR4 in colorectal cancer metastasis.
Int J Cancer. 132:276–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang SX, Loo WT, Chow LW, Yang XH, Zhan Y,
Fan LJ, Zhang F, Chen L, Wang QL, Xiao HL, et al: Decreased
expression of C-erbB-2 and CXCR4 in breast cancer after primary
chemotherapy. J Transl Med. 10 Suppl 1:S32012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ying J, Xu Q, Zhang G, Liu B and Zhu L:
The expression of CXCL12 and CXCR4 in gastric cancer and their
correlation to lymph node metastasis. Med Oncol. 29:1716–1722.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Billah S, Stewart J, Staerkel G, Chen S,
Gong Y and Guo M: EGFR and KRAS mutations in lung carcinoma:
Molecular testing by using cytology specimens. Cancer Cytopathol.
119:111–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Okamoto I: Epidermal growth factor in
relation to tumor development: EGFR-targeted anticancer therapy.
FEBS J. 277:309–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lichtenberger BM, Tan PK, Niederleithner
H, Ferrara N, Petzelbauer P and Sibilia M: Autocrine VEGF signaling
synergizes with EFGR in tumor cells to promote epithelial cancer
development. Cell. 140:268–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor in relation to tumor development: EGFR gene and
cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gajiwala KS, Feng J, Ferre R, Ryan K,
Brodsky O, Weinrich S, Kath JC and Stewart A: Insights into the
aberrant activity of mutant EGFR kinase domain and drug
recognition. Structure. 21:209–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Morrison LE, Jacobson KK, Friedman M,
Schroeder JW and Coon JS: Aberrant EGFR and chromosome 7 associate
with outcome in laryngeal cancer. Laryngoscope. 115:1212–1218.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tzeng CD, Frolov A, Howard JH, Vickers SM,
Buchsbaum DJ, Heslin MJ and Arnoletti JP: 96: Analysis of aberrant
epidermal growth factor rector (EGFR) pathway signaling in
pancreatic cancer patients: Implications for anti-EGFR therapy. J
Surg Res. 137:1912007. View Article : Google Scholar
|
|
46
|
Shen B, Zheng MQ, Lu JW, Jiang Q, Wang TH
and Huang XE: CXCL12-CXCR4 promotes proliferation and invasion of
pancreatic cancer cells. Asian Pac J Cancer Prev. 14:5403–5408.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pei J, Lou Y, Zhong R and Han B: MMP9
activation triggered by epidermal growth factor induced FoxO1
nuclear exclusion in non-small cell lung cancer. Tumour Biol.
35:6673–6678. 2014. View Article : Google Scholar : PubMed/NCBI
|
